Henry Schein (NASDAQ:HSIC) Issues FY 2025 Earnings Guidance

Henry Schein (NASDAQ:HSIC) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 4.800-4.940 for the period, compared to the consensus estimate of 4.970. The company issued revenue guidance of $12.4 billion-$13.2 billion, compared to the consensus revenue estimate of $13.2 billion. Henry Schein also updated its FY25 guidance to $4.80-4.94 EPS.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $75.82 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $9.45 billion, a price-to-earnings ratio of 31.20, a price-to-earnings-growth ratio of 2.13 and a beta of 0.91. Henry Schein has a twelve month low of $63.67 and a twelve month high of $82.63. The business has a 50 day simple moving average of $74.25 and a 200-day simple moving average of $72.43.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the previous year, the firm earned $0.66 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. As a group, equities research analysts expect that Henry Schein will post 4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wells Fargo & Company began coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 target price for the company. Barrington Research restated an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a research report on Wednesday. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and raised their target price for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Finally, Jefferies Financial Group upped their price target on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $80.09.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.